Dapagliflozin
| Subclass of | chemical compound  |
|---|---|
| Get use | Medication |
| Chemical formula | C₂₁H₂₅ClO₆ |
| Canonical SMILES | CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl |
| Isomeric SMILES | CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)Cl |
| Active ingredient in | Farxiga |
| World Health Organisation international non-proprietary name | dapagliflozin |
| Medical condition treated | type-1 diabetes, type 2 diabetes |
| Physically dey interact plus | Solute carrier family 5 member 1, Solute carrier family 5 member 2 |
| Pregnancy category | US pregnancy category C |
| Dema official website | https://www.farxiga.com |
| Subject has role | gliflozins |
Dapagliflozin, dem sell under de brand names Farxiga (US) den Forxiga (EU) among odas, be a medication dem use to treat type 2 diabetes.[1][2][3] E sanso be used to treat adults plus heart failure den chronic kidney disease.[2][4][5] E reversibly dey inhibit sodium-glucose co-transporter 2 (SGLT-2) insyd de renal proximal convoluted tubule to reduce glucose reabsorption den increase urinary glucose excretion.[6]
Common side effects dey include hypoglycaemia (low blood sugar), urinary tract infections, genital infections, den volume depletion (reduced amount of water insyd de body).[7] Diabetic ketoacidosis be a common side effect insyd people plus type 1 diabetes.[8] Serious buh rare side effects dey include Fournier gangrene.[9]
E be developed by Bristol-Myers Squibb in partnership plus AstraZeneca. E dey on de World Health Organization's List of Essential Medicines.[10] Insyd 2023, e be de 92nd most commonly prescribed medication insyd de United States, plus more dan 7 million prescriptions.[11][12] Dapagliflozin be available as a generic medication.[13]
References
[edit | edit source]- ↑ "Farxiga- dapagliflozin tablet, film coated". DailyMed. National Institutes of Health, National Library of Medicine, U.S. Department of Health & Human Services. 3 February 2020. Archived from the original on 30 October 2020. Retrieved 5 May 2020.
- 1 2 "Forxiga EPAR". European Medicines Agency (EMA). 7 December 2012. Archived from the original on 17 February 2020. Retrieved 17 February 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ↑ "Forxiga (dapagliflozin) 5mg should no longer be used for the treatment of Type 1 Diabetes Mellitus". European Medicines Agency (EMA). 11 November 2021. Archived from the original on 11 November 2021. Retrieved 11 November 2021.
- ↑ "FDA approves new treatment for a type of heart failure". U.S. Food and Drug Administration (FDA) (Press release). 5 May 2020. Archived from the original on 6 May 2020. Retrieved 5 May 2020.
- ↑ National Institute for Health and Care Excellence (24 February 2021). "Dapagliflozin for treating chronic heart failure with reduced ejection fraction". NICE Technology Appraisal Guidance [TA679]. NICE. Archived from the original on 9 May 2021. Retrieved 9 May 2021.
- ↑ "BNF: Dapagliflozin". NICE. Retrieved 2 February 2024.
- ↑ Ptaszynska A, Johnsson KM, Parikh SJ, de Bruin TW, Apanovitch AM, List JF (October 2014). "Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events". Drug Safety. 37 (10): 815–829. doi:10.1007/s40264-014-0213-4. PMID 25096959. S2CID 24064402.
- ↑ Dandona P, Mathieu C, Phillip M, Hansen L, Tschöpe D, Thorén F, Xu J, Langkilde AM, et al. (DEPICT-1 Investigators) (December 2018). "Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study". Diabetes Care. 41 (12): 2552–2559. doi:10.2337/dc18-1087. PMID 30352894. S2CID 53027785.
- ↑ Hu Y, Bai Z, Tang Y, Liu R, Zhao B, Gong J, Mei D (2020). "Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System". Journal of Diabetes Research. 2020 3695101. doi:10.1155/2020/3695101. PMC 7368210. PMID 32695827.
- ↑ The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. 2023. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
- ↑ "Top 300 of 2023". ClinCalc. Archived from the original on 12 August 2025. Retrieved 12 August 2025.
- ↑ "Dapagliflozin Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 18 August 2025.
- ↑ "Generic Farxiga Availability". Drugs.com. 6 November 2024. Retrieved 30 November 2024.
External links
[edit | edit source]